Angiotech Pharma Looks To Become Less Reliant On Device Partners
This article was originally published in The Pink Sheet Daily
Executive Summary
Dependence on Boston Scientific's Taxus royaltieis will fall significantly once Angiotech offers AMI's oncology, aesthetic, wound closure and ophthalmology devices.